New drug trial aims to protect Kids' kidneys from IgA nephropathy

NCT ID NCT07498335

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This phase 3 trial tests the drug atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The study measures whether atrasentan reduces protein in the urine, a sign of kidney damage, over 36 weeks. All participants receive the drug, and researchers will also check safety and how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atrasentan
What this could lead to: If successful, this could provide a new treatment option to slow kidney damage and control IgA nephropathy in children.
What could go wrong: This is a small, single-arm study with no placebo group, so results may be less reliable. Atrasentan may not work as well in children as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BERGER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome glomerulonephritis IgA glomerulonephritis IgA nephropathy, susceptibility to, 1 kidney disorder urinary system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BERGER DISEASE BERGERS DISEASE IGA NEPHROPATHY IMMUNOGLOBULIN A NEPHROPATHY NEPHRITIS IGA TYPE, NEPHROPATHY IGA TYPE PRIMARY IGAN

Contacts and locations

Locations

Cincinnati Childrens Hospital MC
NOT_YET_RECRUITING

Cincinnati, Ohio, 45229, United States
Hackensack Meridian Health
NOT_YET_RECRUITING

Neptune City, New Jersey, 07753, United States
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Nagoya, Aichi-ken, 4578510, Japan
Novartis Investigative Site
RECRUITING

Chiba, 2608712, Japan
Novartis Investigative Site
RECRUITING

Fukuoka, 815-8555, Japan
Novartis Investigative Site
RECRUITING

Seoul, Seoul, 03080, South Korea
University of Oklahoma Health Science Center
NOT_YET_RECRUITING

Oklahoma City, Oklahoma, 73104, United States
University of Tennessee Health Science Center- Le Bonheur Research Center
NOT_YET_RECRUITING

Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.